NanoView Biosciences, a Boston, MA-based emerging leader in the field of exosome detection and characterization, closed a $10m Series B financing.
The round was led by Northpond Ventures, with participation from existing investors Sands Capital Ventures and PBM Capital Group.
The company intends to use the funds to complete development of the ExoView system.
Led by Jerry Williamson, Chief Executive Officer, NanoView is advancing an innovative instrument and consumables platform that efficiently and accurately enables complete detection and characterization of extracellular vesicles, including exosomes. Exosomes are nanoscale extracellular vesicles secreted by most cell types and represent the communication system between cells.
FinSMEs
10/10/2018